Intelligent Screening and Precision Diagnosis of Prostate Cancer Based on Multimodal Data

This project aims to develop a precision screening and diagnostic solution for prostate cancer based on multimodal artificial intelligence, focusing on addressing the diagnostic challenge in patients within the PSA "gray zone" of 4-10 ng/mL. The project will integrate multidimensional information including ctDNA liquid biopsy, routine laboratory data, and prostate ultrasound images to develop three models: a ctDNA-based multimodal AI prediction model, a routine laboratory data-assisted decision model, and an ultrasound image AI-assisted diagnostic model. On this basis, a multimodal AI fusion decision system will be established to automatically generate individualized risk assessment reports and diagnostic recommendations. Additionally, a closed-loop mechanism of "clinical use - data feedback - model optimization" will be constructed to continuously iterate model parameters using pathological gold standards, thereby improving predictive accuracy in our hospital population. The project will form a generalizable precision diagnostic workflow, reduce unnecessary biopsies in "gray zone" patients, and provide an implementable in-hospital solution for precision medicine in prostate cancer.

NCT Number	NCT07631806
Lead Sponsor	Guangxi Medical University
Conditions	Prostate Cancer With PSA Gray Zone
Enrollment	500 participants
Start Date	2026-05-01
Primary Completion	2028-05-01 (estimated)
Study Completion	2028-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-17